AB122 Platform Study

ABSTRACT: This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.

DISEASE(S): Adenocarcinoma,Colorectal Cancer,Non-small Cell Lung Cancer,Gastric Cancer,Advanced Or Metastatic Solid Tumor,Pancreatic Ductal Adenocarcinoma

PROVIDER: 2386215 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR